FHA
MACK

Flagship Harbor Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Flagship Harbor Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed – – 2013
2020
Q3 		$0 Hold
20
– – ﹤0.01% 2256
2020
Q2 		$0 Hold
20
– – ﹤0.01% 2237
2020
Q1 		$0 Hold
20
– – ﹤0.01% 2049
2019
Q4 		$0 Hold
20
– – ﹤0.01% 2010
2019
Q3 		$0 Sell
20
-5
-20% -$25 ﹤0.01% 2045
2019
Q2 		$0 Hold
25
– – ﹤0.01% 2040
2019
Q1 		$0 Hold
25
– – ﹤0.01% 2026
2018
Q4 		$0 Hold
25
– – ﹤0.01% 2227
2018
Q3 		$0 Hold
25
– – ﹤0.01% 2189
2018
Q2 		$0 Buy
+25
New +$166 ﹤0.01% 2117

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Flagship Harbor Advisors's MACK Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2020, closing a stake of 20 shares.

Flagship Harbor Advisors first reported a position in MACK in Q2 2018 and held it in 10 quarters. The position peaked at $0 in Q3 2020. 40 funds tracked by Wall St. Rank hold MACK as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 20 Merrimack Pharmaceuticals, Inc. shares in Q4 2020.
  • Flagship Harbor Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 10 quarters.
  • Flagship Harbor Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $0 in Q3 2020.
  • 40 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.